OSE IMMUNOTHERAPEUTICS EUR0.20 financial statements, including revenue, expenses, and profit

The total revenue of 0RAD for the last semiannual is 831.00 k EUR, and it's 98.80% lower compared to the previous semiannual. The net income of H2 24 is -19.73 M EUR.